Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells
Yıl: 2020 Cilt: 44 Sayı: 1 Sayfa Aralığı: 15 - 23 Metin Dili: İngilizce DOI: 10.3906/biy-1909-12 İndeks Tarihi: 30-04-2020
Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells
Öz: One of the most challenging problems in colorectal cancer (CRC) is resistance to chemotherapy drugs such as doxorubicin(DOX). The programmed death ligand-1 (PD-L1) is related to chemoresistance and is overexpressed in several human cancer cell types.Here, we investigated the changes in the expression of PD-L1 in DOX-treated CRC and breast cancer (BRC) cells. Also, to addressPD-L1 regulation, we assessed expression levels of miR-140 and miR-34a, two microRNAs that can target the 3’ UTR region of thegene encoding PD-L1. HCT116 CRC and MDA-MB-231 BRC cells were treated with various doses of DOX in culture and PD-L1expression was quantified using qRT-PCR, flow cytometry, and western blot analysis. We also evaluated PD-L1 localization in HCT116cells by immunofluorescence. Next, we assessed expression of miR-140 and miR-34a in DOX-treated HCT116 and MDA-MB-231cells. Finally, we investigated whether miR-140 targets the 3’ UTR of the gene encoding PD-L1 in HCT116 cells using the p2FP-RNAiRNAi reporter vector system. PD-L1 expression in HCT116 cells, while low at baseline, can be induced by treatment with 0.5 µM DOX.MDA-MB-231 baseline PD-L1 expression exceeded HCT116 cell maximal expression and decreased following DOX treatment. Wefurther demonstrated that PD-L1 localizes to the cell surface in DOX-treated HCT116 cells. While miR-140 expression decreased inDOX-treated HCT116 cells, it increased in DOX-treated MDA-MB-231 cells. MiR-34a expression increased in both DOX-treated celltypes. Finally, we present evidence for the regulation of PD-L1 by miR-140 in HCT116 cells. PD-L1 expression can increase followingtreatment with DOX in HCT116 cells but decrease in MDA-MB-231 cells, suggesting a distinct response to DOX in these two differentcancer types. Also, a negative correlation between PD-L1 and miR-140 was observed in DOX-treated HCT116 cells, but not in MDAMB-231 cells.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Black M, Barsoum IB, Truesdell P, Cotechini T, MacdonaldGoodfellow SK et al. (2016). Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget 7 (9): 10557- 67.
- Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ et al. (2015). PD-L1 regulation by p53 via miR-34. Journal of the National Cancer Institute 108 (1): djv303.
- Ewer MS, Ewer SM (2015). Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology 12 (9): 547-558.
- Ghebeh H, Lehe C, Barhoush E, Al-Romaih K, Tulbah A et al. (2010). Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Research 12 (4): R48.
- Huang X, Xie X, Wang H, Xiao X, Yang L et al. (2017). PDL1 and LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a. Journal of Experimental & Clinical Cancer Research 36 (1): 129.
- Ji X, Wang E, Tian F (2018). MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling. Biochemical and Biophysical Research Communications 495 (1): 1342-8.
- Li CW, Lim SO, Xia W, Lee HH (2016). Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications 7: 12632.
- Midgley R, Kerr DJ (2005). Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nature Clinical Practice Oncology 2 (7): 364-369.
- Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews 56 (2): 185-229.
- Moertel CG (1994). Chemotherapy for colorectal cancer. New England Journal of Medicine 330 (16): 1136-1142.
- Park HJ, Kusnadi A, Lee EJ, Kim WW, Cho BC et al. (2012). Tumorinfiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cellular Immunology 278 (1- 2): 76-83.
- Rom-Jurek EM, Kirchhammer N, Ugocsai P, Ortmann O, Wege AK et al. (2018). Regulation of programmed death ligand 1 (PD-L1) expression in breast cancer cell lines in vitro and in immunodeficient and humanized tumor mice. International Journal of Molecular Sciences 19 (2): 563.
- Selenko-Gebauer N, Majdic O, Szekeres A, Hofler G, Guthann E et al. (2003). B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. Journal of Immunology 170 (7): 3637-3644.
- Sznol M, Chen L (2013). Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clinical Cancer Research 19 (5): 1021-1034.
- Tamura H, Dong H, Zhu G, Sica GL, Flies DB et al. (2001). B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 97 (6): 1809-1816.
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine 366 (26): 2443-2454.
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J et al. (2012). Global cancer statistics. Cancer Journal for Clinicians 65 (2): 87-108.
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America 103 (7): 2257-2261.
- Wang Q, Lin W, Tang X, Li S, Guo L et al. (2017). The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. International Journal of Molecular Sciences 18 (12): E2540.
- Wang X, Li J, Dong K, Lin F, Long M et al. (2015). Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cellular Signalling 27 (3): 443-452.
- Wei R, Cao G, Deng Z, Su J, Cai L (2016). MiR-140-5p attenuates chemotherapeutic drug-induced cell death by regulating autophagy through inositol 1,4,5-trisphosphate kinase 2 (IP3k2) in human osteosarcoma cells. Bioscience Reports 36 (5): e00392.
- Wu P, Wu D, Li L, Chai Y, Huang J (2015). PD-L1 and survival in solid tumors: a meta-analysis. PLoS One 10 (6): e0131403.
- Xie WB, Liang LH, Wu KG, Wang LX, He X et al. (2018). MiR-140 expression regulates cell proliferation and targets PD-L1 in NSCLC. Cellular Physiology and Biochemistry 46 (2): 654-663.
- Zang X, Allison JP (2007). The B7 family and cancer therapy: costimulation and coinhibition. Clinical Cancer Research 13 (18 Pt 1): 5271-5279.
- Zhu JN, Fu YH, Hu ZQ, Li WY, Tang CM et al. (2017). Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicininduced cardiotoxicity. Scientific Reports 7 (1): 11879.
- Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A et al. (2008). The anticancer immune response: indispensable for therapeutic success? Journal of Clinical Investigation 118 (6): 1991-2001.
| APA | NABA N, TOLAY N, erman b, SAYI YAZGAN A (2020). Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. , 15 - 23. 10.3906/biy-1909-12 |
| Chicago | NABA Noel Mopouguini,TOLAY Nazife,erman batu,SAYI YAZGAN Ayça Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. (2020): 15 - 23. 10.3906/biy-1909-12 |
| MLA | NABA Noel Mopouguini,TOLAY Nazife,erman batu,SAYI YAZGAN Ayça Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. , 2020, ss.15 - 23. 10.3906/biy-1909-12 |
| AMA | NABA N,TOLAY N,erman b,SAYI YAZGAN A Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. . 2020; 15 - 23. 10.3906/biy-1909-12 |
| Vancouver | NABA N,TOLAY N,erman b,SAYI YAZGAN A Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. . 2020; 15 - 23. 10.3906/biy-1909-12 |
| IEEE | NABA N,TOLAY N,erman b,SAYI YAZGAN A "Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells." , ss.15 - 23, 2020. 10.3906/biy-1909-12 |
| ISNAD | NABA, Noel Mopouguini vd. "Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells". (2020), 15-23. https://doi.org/10.3906/biy-1909-12 |
| APA | NABA N, TOLAY N, erman b, SAYI YAZGAN A (2020). Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. Turkish Journal of Biology, 44(1), 15 - 23. 10.3906/biy-1909-12 |
| Chicago | NABA Noel Mopouguini,TOLAY Nazife,erman batu,SAYI YAZGAN Ayça Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. Turkish Journal of Biology 44, no.1 (2020): 15 - 23. 10.3906/biy-1909-12 |
| MLA | NABA Noel Mopouguini,TOLAY Nazife,erman batu,SAYI YAZGAN Ayça Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. Turkish Journal of Biology, vol.44, no.1, 2020, ss.15 - 23. 10.3906/biy-1909-12 |
| AMA | NABA N,TOLAY N,erman b,SAYI YAZGAN A Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. Turkish Journal of Biology. 2020; 44(1): 15 - 23. 10.3906/biy-1909-12 |
| Vancouver | NABA N,TOLAY N,erman b,SAYI YAZGAN A Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. Turkish Journal of Biology. 2020; 44(1): 15 - 23. 10.3906/biy-1909-12 |
| IEEE | NABA N,TOLAY N,erman b,SAYI YAZGAN A "Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells." Turkish Journal of Biology, 44, ss.15 - 23, 2020. 10.3906/biy-1909-12 |
| ISNAD | NABA, Noel Mopouguini vd. "Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells". Turkish Journal of Biology 44/1 (2020), 15-23. https://doi.org/10.3906/biy-1909-12 |
